Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial

William HK Schilling, Podjanee Jittamala, Phrutsamon Wongnak, James A Watson, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M. Batty, Ellen M. Beer, Shivani Singh, Tanatchakorn Asawasriworanan, Timothy Seers, Koukeo Phommasone, Terry John Evans, Varaporn Kruabkontho, Thatsanun Ngernseng, Jaruwan Tubprasert, Mohammad Yazid Abdad, Wanassanan Madmanee, Jindarat Kouhathong, Kanokon Suwannasin, Watcharee Pagornrat, Tianrat Piteekan, Borimas Hanboonkunupakarn, Kittiyod Poovorawan, Manus Potaporn, Attasit Srisubat, Bootsakorn Loharjun, Kesinee Chotivanich, Mallika Imwong, Sasithon Pukrittayakamee, Arjen M. Dondorp, Nicholas Day, Watcharapong Piyaphanee, Weerapong Phumratanaprapin, Sir Nicholas White (2025). Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial. , DOI: https://doi.org/10.1016/s1473-3099(25)00482-7.